anti-gd2 antibody-drug conjugate m3554
Generic: Anti-GD2 Antibody-drug Conjugate M3554
anti-gd2 antibody-drug conjugate m3554: 1 clinical trial tracked.
anti-gd2 antibody-drug conjugate m3554 evidence translation
What we can confirm
1 tracked trial
No verified listed company relationship
What it means
AI will separate confirmed drug evidence from unknown company context.
What to watch
Watch trial status, endpoints, and the next source-backed update.
BioSniper AIPage evidence connected
Prepared research question
What is verified about anti-gd2 antibody-drug conjugate m3554, and what remains unknown?
Run cited research
Traceable citations · Unknowns marked
See linked entities and source evidence1 indications · 0 study sponsors
Related indications
Study sponsors
No additional listed-company sponsor is linked.
Clinical Trial Registry Records (1)
A Phase 1, Two-Part, Multicenter, Open-Label First in Human Study of Anti-GD2 Antibody Drug Conjugate M3554 in Participants With Advanced Solid Tumors
Primary endpoint: Number of Participants with Dose Limiting Toxicities (DLTs) and Adverse Events (AEs)
Interventionalopen52 targetStarted 2024-11Completion 2027-0411 sites · Belgium, France, Japan, Switzerland…EMD Serono Research & Development Institute, Inc.